Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are trying to get liquidity. They will let the shares hit the market and then start releasing all the things they have been working on to drive liquidity which is needed. I expect to hear of changing to the more stringent OTC market and to learn of various agreements that have been put into place. This will get the liquidity and drive share price back up.
Just got off the phone with Fidelity and they are honoring my transfer. (Note: I do have a corporate retirement account with them among a few others so I don't know if that is encouraging them to honor it or not)
Thank you for your D&D.
I agree with you but also think liquidity has been a huge issue here. I'm happy to see more volume even though the share price is nearly down 50%. I do know that those who participated in the private placement should have their initial limited shares coming due soon and i can't say there won't been a sell off but I also look for the company to release some awesome news very soon to help drive liquidity and get more shares trading. I can say I know several of these private placement holders and their numbers are not this low to sell their shares so though some may let their shares go this cheap I don't suspect most will.
Claim: “How many patents do you think Zeevi owns? This should be fun! “
Claim Answered: Around 50. Here are most of them
Patents by Inventor Oron Yacoby-Zeevi
Oron Yacoby-Zeevi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
• OPIPRAMOL PATCH
Publication number: 20180140610
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of active agents such as opipramol. More particularly, the disclosed transdermal compositions include an active agent; one or more plasticizers; one or more penetration enhancers; a pressure-sensitive adhesive; and may include one or more hydrophilic polymers.
Type: Application
Filed: September 18, 2015
Publication date: May 24, 2018
Applicant: NeuroDerm, Ltd.
Inventors: Oron YACOBY-ZEEVI, Mara NEMAS
• CRYSTAL FORMS OF APOMORPHINE AND USES THEREOF
Publication number: 20170368052
Abstract: The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms such as acid addition salts of apomorphine, because of their increased/greater stability and/or improved pharmacological properties, e.g., decreased adverse reactions at the site of administration. The invention further provides liquid formulations obtained by dissolving said crystalline forms of apomorphine in a solvent, as well as a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, or a condition associated therewith, by administration of said liquid formulations.
Type: Application
Filed: December 23, 2015
Publication date: December 28, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Jonathan Cummins, Petra Dieterich
• PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF
Publication number: 20170296491
Abstract: The present invention discloses various aqueous pharmaceutical compositions comprising a levodopa amide compound, or a salt thereof, which are stable for at least 24 hours at room temperature, and use thereof in treatment of diseases or disorders characterized by neurodegeneration and/or reduced levels of brain dopamine, e.g., Parkinson's disease.
Type: Application
Filed: November 23, 2016
Publication date: October 19, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik, Irena Vainshtok, Einat Sela
• Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20170196828
Abstract: Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.
Type: Application
Filed: August 23, 2016
Publication date: July 13, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME
Publication number: 20170157077
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: July 13, 2016
Publication date: June 8, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE AGENTS
Publication number: 20170157076
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Application
Filed: July 8, 2016
Publication date: June 8, 2017
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik
• DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS
Publication number: 20170157079
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Type: Application
Filed: February 21, 2017
Publication date: June 8, 2017
Inventor: Oron Yacoby-Zeevi
• Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
Patent number: 9421267
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Grant
Filed: November 15, 2011
Date of Patent: August 23, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Compositions for transdermal delivery of active agents
Patent number: 9415108
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Grant
Filed: November 15, 2011
Date of Patent: August 16, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawoznik
• Compositions comprising apomorphine and organic acids and uses thereof
Patent number: 9381249
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly compositions comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Grant
Filed: November 18, 2015
Date of Patent: July 5, 2016
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20160151317
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: July 1, 2015
Publication date: June 2, 2016
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF
Publication number: 20160067339
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly compositions comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Application
Filed: November 18, 2015
Publication date: March 10, 2016
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• METHOD FOR TREATMENT OF PARKINSON'S DISEASE
Publication number: 20160022573
Abstract: The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.
Type: Application
Filed: March 13, 2014
Publication date: January 28, 2016
Applicant: NEURODERM, LTD.
Inventor: Oron Yacoby-Zeevi
• DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS
Publication number: 20150352212
Abstract: Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations.
Type: Application
Filed: March 12, 2015
Publication date: December 10, 2015
Inventor: Oron Yacoby-Zeevi
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9101663
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: December 7, 2010
Date of Patent: August 11, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF
Publication number: 20150182523
Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.
Type: Application
Filed: June 5, 2013
Publication date: July 2, 2015
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9040589
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 13, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
Patent number: 9040578
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Grant
Filed: April 2, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
Patent number: 9040577
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Grant
Filed: April 2, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9040590
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 13, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 9040590
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 13, 2014
Date of Patent: May 26, 2015
Assignee: NeuroDerm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20140249230
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: May 13, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME
Publication number: 20140249228
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: April 2, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS FOR SAME
Publication number: 20140249229
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: April 2, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20140249231
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: May 13, 2014
Publication date: September 4, 2014
Applicant: NEURODERM, LTD.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors and Compositions for Same
Publication number: 20140051755
Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.
Type: Application
Filed: November 15, 2011
Publication date: February 20, 2014
Applicant: Neuroderm LTD
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Compositions for Transdermal Delivery of Active Agents
Publication number: 20130338143
Abstract: Disclosed herein are compositions that are useful in effecting the transdermal delivery of therapeutic agents. More particularly, the disclosed transdermal compositions may include a fatty alcohol (for example, octanol), a terpene (for example, limonene), and an active agent comprising an amine moiety.
Type: Application
Filed: November 15, 2011
Publication date: December 19, 2013
Applicant: Neuroderm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas, Eduardo Zawozink
• Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20130253056
Abstract: Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.
Type: Application
Filed: March 12, 2013
Publication date: September 26, 2013
Applicant: Neuroderm, Ltd.
Inventors: Mara Nemas, Oron Yacoby-Zeevi
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 8193243
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: May 17, 2010
Date of Patent: June 5, 2012
Assignee: Neuroderm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20110269833
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: December 7, 2010
Publication date: November 3, 2011
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous administration of dopa decarboxylase inhibitors and compositions for same
Patent number: 7863336
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Grant
Filed: July 14, 2010
Date of Patent: January 4, 2011
Assignee: Neuroderm, Ltd.
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20100298429
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: July 14, 2010
Publication date: November 25, 2010
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Continuous Administration of Dopa Decarboxylase Inhibitors and Compositions for Same
Publication number: 20100298428
Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
Type: Application
Filed: May 17, 2010
Publication date: November 25, 2010
Inventors: Oron Yacoby-Zeevi, Mara Nemas
• Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
Publication number: 20060269552
Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.
Type: Application
Filed: June 3, 2004
Publication date: November 30, 2006
Inventors: Oron Yacoby-Zeevi, Tuvia Peretz, Daphna Miron, Yinon Shlomi, Iris Pecker, Maty Ayal-Hershkovitz
• Methods of and pharmaceutical compositions for improving implantation of embryos
Publication number: 20060008892
Abstract: Methods of improving embryo implantation are disclosed and comprise contacting a receptive uterus and/or an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.
Type: Application
Filed: June 17, 2005
Publication date: January 12, 2006
Applicant: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
• Therapeutic and cosmetic uses of heparanases
Publication number: 20050260187
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: April 15, 2005
Publication date: November 24, 2005
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker, Elena Feinstein
• Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
Publication number: 20040213789
Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.
Type: Application
Filed: August 22, 2003
Publication date: October 28, 2004
Inventors: Oron Yacoby-Zeevi, Tuvia Peretz, Daphna Miron, Yinon Shlomi, Iris Pecker, Maty Ayal-Hershkovitz, Elena Feinstein, Joel M. Van Gelder, Israel Vlodavsky, Yael Friedmann
• Introducing a biological material into a patient
Publication number: 20040175371
Abstract: A biological preparation is provided and includes a biological material and a purified, natural or recombinant, extracellular matrix degrading enzyme being externally adhered thereto.
Type: Application
Filed: March 15, 2004
Publication date: September 9, 2004
Inventor: Oron Yacoby-Zeevi
• Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
Publication number: 20040170631
Abstract: Specific anti-heparanase antibodies which bind specifically to heparanase having sequence homology to human heparanase, which can be used to treat and diagnose conditions associated with heparanase catalytic activity, for purification of heparanase, and for drug development in heparanase associated conditions are disclosed.
Type: Application
Filed: November 28, 2003
Publication date: September 2, 2004
Inventors: Oron Yacoby-Zeevi, Tuvia Peretz, Daphna Miron, Yinon Shlomi, Iris Pecker, Maty Ayal-Hershkovitz, Elena Feinstein, Joel M. Van Gelder, Israel Vlodavsky, Yael Friedmann
• Therapeutic and cosmetic uses of heparanases
Publication number: 20040146497
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: February 20, 2004
Publication date: July 29, 2004
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker, Elena Feinstein
• Methods and kits utilizing heparanase as a diagnostic marker for haemostatic disorders
Publication number: 20040132123
Abstract: Provided is a method of determining a presence, absence, or severity of a haemostatic disorder in a subject. The method is effected by determining a level of heparanase expression or activity in a biological sample obtained from the subject. Also provided are kits for use with the method.
Type: Application
Filed: October 23, 2003
Publication date: July 8, 2004
Inventor: Oron Yacoby-Zeevi
• Use of ecm degrading enzymes for the improvement of cell transplantation
Publication number: 20040033218
Abstract: Cell preparations which comprise cells carrying an extracellular matrix degrading enzyme and methods of using such cell preparations for improving transplantation efficiency of such cells.
Type: Application
Filed: June 12, 2003
Publication date: February 19, 2004
Inventor: Oron Yacoby-Zeevi
• Therapeutic and cosmetic uses of heparanases
Publication number: 20030161823
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: January 14, 2003
Publication date: August 28, 2003
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker, Elena Feinstein
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Publication number: 20030068806
Abstract: A method of purifying a recombinant heparanase from overexpressing cells or growth medium which comprises adsorbing said recombinant heparanase on an ion-exchange column under low salt conditions, washing said column with low salt solution thereby eluting other proteins, and eluting the recombinant heparanase from said column by a salt gradient or higher salt concentration.
Type: Application
Filed: May 3, 2002
Publication date: April 10, 2003
Inventors: Maty Ayal-Hershkovitz, Iris Pecker, Oron Yacoby-Zeevi
• Method of inducing bone formation
Publication number: 20030031660
Abstract: A method of inducing bone formation in a subject in need thereof, the method comprises administering to the subject a therapeutically effective amount of heparanase. A pharmaceutical composition for inducing bone formation in a subject in need thereof, the pharmaceutical composition comprises, as an active ingredient, a therapeutically effective amount of heparanase, and a pharmaceutically acceptable carrier.
Type: Application
Filed: June 7, 2002
Publication date: February 13, 2003
Applicant: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Patent number: 6475763
Abstract: Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis.
Type: Grant
Filed: January 19, 2000
Date of Patent: November 5, 2002
Assignee: Insight Strategy & Marketing Ltd.
Inventors: Maty Ayal-Hershkovitz, Haim Moskowitz, Daphna Miron, Ayelet Gilboa, Madlene Mimon, Hanna Ben-Artzi, Oron Yacoby-Zeevi, Iris Pecker, Yoav Peleg, Yinon Shlomi
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Patent number: 6426209
Abstract: A preparation containing an enzymatically inactive form of heparanase, said enzymatically inactive form of heparanase being cleavable into an enzimatically active form of heparanase.
Type: Grant
Filed: August 10, 2000
Date of Patent: July 30, 2002
Assignee: Insight Strategy Marketing Ltd.
Inventors: Maty Ayal-Hershkovitz, Iris Pecker, Oron Yacoby-Zeevi
• Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria
Patent number: 6423312
Abstract: A method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.
Type: Grant
Filed: August 27, 1998
Date of Patent: July 23, 2002
Assignee: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
• Methods of and pharmaceutical compositions for improving implantation of embryos
Publication number: 20020088019
Abstract: Methods of improving embryo implantation are disclosed and comprise contacting a receptive uterus and/or an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.
Type: Application
Filed: October 17, 2001
Publication date: July 4, 2002
Inventor: Oron Yacoby-Zeevi
• Therapeutic and cosmetic uses of heparanases
Publication number: 20020068054
Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.
Type: Application
Filed: December 4, 2000
Publication date: June 6, 2002
Applicant: Insight Strategy & Marketing Ltd. and Hadasit Medical Research Services and Development Ltd.
Inventors: Neta Ilan, Israel Vlodavsky, Oron Yacoby-Zeevi, Iris Pecker
• COMPOSITIONS INCLUDING GLYCOSAMINOGLYCANS DEGRADING ENZYMES AND USE OF SAME AGAINST SURFACE PROTECTED BACTERIA
Publication number: 20020064858
Abstract: A method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.
Type: Application
Filed: August 27, 1998
Publication date: May 30, 2002
Inventor: ORON YACOBY-ZEEVI
• Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
Patent number: 6348344
Abstract: Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis.
Type: Grant
Filed: March 2, 1999
Date of Patent: February 19, 2002
Assignee: Insight Strategy & Marketing Ltd.
Inventors: Maty Ayal-Hershkovitz, Haim Moskowitz, Daphna Miron, Ayelet Gilboa, Madelene Mimon, Hanna Ben-Artzi, Oron Yacoby-Zeevi, Iris Pecker, Yoav Peleg, Yinon Schlomi
• INTRODUCING A BIOLOGICAL MATERIAL INTO A PATIENT
Publication number: 20010006630
Abstract: A biological preparation is provided and includes a biological material and a purified, natural or recombinant, extracellular matrix degrading enzyme being externally adhered thereto.
Type: Application
Filed: March 2, 1999
Publication date: July 5, 2001
Inventor: ORON YACOBY-ZEEVI
• Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
Patent number: 6153187
Abstract: A method of managing a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans, the method comprising the step of administering at least one glycosaminoglycans degrading enzyme to the patient in an amount therapeutically effective to reduce at least one of the following: the visco-elasticity of the material, pathogens infectivity and inflammation. An article of manufacture comprising an inhaler including, as an active ingredient, at least one glycosaminoglycans degrading enzyme for generating aerosols including the enzyme for management a patient having an accumulation of mucoid, mucopurulent or purulent material containing glycosaminoglycans.
Type: Grant
Filed: March 25, 1998
Date of Patent: November 28, 2000
Assignee: Insight Strategy & Marketing Ltd.
Inventor: Oron Yacoby-Zeevi
Here is the newest update/answers based on what is communicated by the company.
Cheers!
Claim: "Why doesn't OWCP submit patent applications to the USPTO?
I think we all know - OWCP couldn't deal with the rigors of the FDA and the patent applications"
Claim Rejected: Check out USTPO website for a family of 9 registered patents and a total of 31 patents.
Claim: “I guarantee they will never post the patent applications..”
Claim Rejected: Just check out USPTO and other international patent registration sites. here is one! https://www.uspto.gov/patents-application-process/search-patents
Claim: “Registered patents are meaningless”
Claim Rejected: MIT Scientists’ information on the importance of patent registrations…
http://web.mit.edu/e-club/hadzima/the-importance-of-patents.html
Claim: “all patent claims submitted to the USPTO have been rejected"
Claim Rejected: They are still there on the website, just updated like thousands of other companies’ patents. GW** last patent took 5 years of updates to finally get granted.
https://www.uspto.gov/patents-application-process/search-patents
Claim: “There is zero proof that OWCP has done any clinical trials/studies.”
Claim: “you have absolutely no proof that Sheba is doing any research with OWCP”.
Claim Rejected: Careful Reading required!
"OWC Pharmaceutical Research Corp. (“OWC”) through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., announces the successful completion of the first part of its Phase I, placebo controlled, maximal dose study (the “Psoriasis Study”) to determine the safety and tolerability of topical ointment containing medical grade cannabis (the “Topical Ointment”) in healthy volunteers. The study is being performed by Professor Aviv Barzilai, Director of the Department of Dermatology at Chaim Sheba Medical Center. Sheba is a university-affiliated hospital that serves as Israel’s national medical center and is one of the leading integrated medical centers in the Middle East. The completed part of the study consisted of application of escalating doses of the Topical Ointment to healthy volunteers and was successfully completed with no adverse effects. After completion of the second part of this study, the company plans to initiate a phase II clinical study to demonstrate the efficacy of Topical Ointment in treating mild to moderate psoriasis and other inflammatory skin diseases.
Claim: “There are 7 patents that have been applied for in multiple places”
Claim Rejected:
Much better than "no patent" baseless claim. Good!
$OWCP USPTO Patent link (9 patent families, 31 patents, and counting) All patents are still active. These registered patents are being updated.
United States Patent and Trademark Office (USPTO)
https://www.uspto.gov/patents-application-process/search-patents
Claim: "OWCP has to file a S-1 and the SEC has to declare it effective - with OWCP being investigated by the SEC it will never be deemed effective"
Claim Rejected: SEC already declared S-1 effective! smile
Claim: “The S-1 being declared effective is harmful to shareholders”
Claim Rejected:
Thousands of companies yet go through a lot of pain to get their S-1 approved so they can issue shares to get funded to continue their business operations?
Claim: “First, the $5 million isn't guaranteed - you need to read the Equity Purchase Agreement - OWCP has to file a S-1 and the SEC has to deem it effective - that won't happen since there is a ongoing investigation. “
“OWCP has 60 days to file a S-1.”
Then, quietly after SEC approved $OWCP S-1…
Claim Rejected by ITSELF!: “OWCP doesn't receive $5 million in one lump sum - it is in tranches”
Claim: “The massive dilution has begun with the filing of Form 424B3!”
Claim Rejected Priced at 0.2 and 0.22
April 2018 Private Placement
On April 30, 2018, we entered into and consummated a Securities Purchase Agreement (the “Purchase Agreement”) with a non-US-based institutional investor (the “Investor”). Under the terms and conditions of the Purchase Agreement, we sold and the Investor bought, (i) 500 shares of our new series of preferred stock designated as Series A Preferred Stock (the “Series A Preferred Shares”), which, as of April 30, 2018, were convertible into 25,000,000 shares of our common stock at a conversion price of $0.20 per share, subject to adjustment pursuant to the anti-dilution provisions of the Preferred Shares, and (ii) warrants representing the right to acquire 12,500,000 shares of our common stock at an exercise price of $0.22 per share (the “Warrants”), subject to adjustment pursuant to the anti-dilution provisions of the Warrants, for an aggregate purchase price of $5,000,000
Claim: “ they were lead to believe that OWCP owned 7 patents“
Claim rejected itself: “There are 7 patents that have been applied for in multiple places”
Claim: “The latest storyline is that the "psoriasis cream" has completed Phase 1 studies “
Claim Rejected: The correct storyline is that the psoriasis cream has completed the Part 1 of Phase 1 studies.
Claim: “OWCP has not done any new research since 2014.”
Claim Rejected: Check out the updates on USPTO and WIPO sites. Many company's research has been updated there in 2018. This is the newest one. Multiple Myeloma US Patent Application has been published on 7/5/2018.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US222841762&recNum=1&tab=NatCollDocuments&maxRec=32&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString="one+world+cannabis";;;
It is definitely obvious there has been a positive change in OWCP from what has been in place the last few years to the leadership that is there today.
Yes we all wish OWCP was further along but I think the point is that positive traction is being made and with each day we are approaching the time when OWCP have licensing agreements.
Here is the thing. If you are a buy an hold investor. Drop 30 or 40 grand for some shares and in a year maybe a year and a half and it will be worth a million or more (assuming OWCP stays the course which they have proven they are and intend to continue to do)
If it dips to 0.18 cents I'm picking up another 200k shares.
TD told me they wouldn't transfer the shares but Fidelity is going to.
Here is what I believe to be the published study. Can't read the whole article but maybe someone has access to it and can post for all. This just came out in the Journal of Controlled Release and Dr. Aviv Barzilai is an author.
https://www.researchgate.net/publication/325530481_Ultrasound_targeting_of_Q-starchmiR-197_complexes_for_topical_treatment_of_psoriasis
Many very large shareholders still holding strong. Just went dark because this board can be exhausting and nothing of substance yet.... and there are other ways we can keep in touch.
Just sticking my head back in the door here. Still holding strong and long. Considering doubling down if the PPS drops any lower. Seems silly to me we are at this level of market cap for what OWCP really has but I also have had my frustrations and understand. I'm not trading this stock and there is a dying market for that here now which is good. I suspect to see slow and steady climbs though for the next year as OWCP leadership starts to show they have been performing.
All the best to you.
Well NTVA did a good job. I have spoken with then about not wanting to do new warrant purchases until my other shares (at least in part) had been released... They did... So now I guess I need to wire them some money and hold up my commitment to them.
They were supposed to have cleared more than 6 months ago. Their excuse for an update has been that they are working with the SEC to move things forward. Oddly enough we are approaching a year and the story is the same.
Oh I don't plan to liquidate immediately but by association to Friedland I don't want to put more money here until I have access to what I currently have invested. Hopefully we all see a lot of possible news and upward momentum but until the SEC clears the private placement shares I'm not putting more in here.
Yes great news however until they get the private placement shares unrestricted (which is nearing a year at this point) it's all for not. It does no good if you can't trade the stock if you want to. Hopefully soon. As many others who invested through the private placement... they will not get any more money from me for warrants until I have access to my initial shares.
Lets hope. I'm not spending anything else here until I have access to my shares that were paid for nearly a year ago.
Think the company is great and there is a lot of up potential but until the SEC allows shares to be issued I'm done here and have enough.
My thoughts also
That makes no sense... We tanked today and not tomorrow... does that mean Clays following pumps this tomorrow?... you know the inverse.
About time. Not really comfortable buying more warrants without knowing things are moving. It's been ridiculous and I think many who invested feel somewhat mislead on when they would have access to their shares.
Which is coming per the wall street conference not later than end of Q3 for California cream distribution... But here is the kicker. Australia just said they will accept cannabis imports... Israel said they will now export... Where are some of our patents? Just saying we may have had an unforeseen bonus.
I agree completely. He made 7.5 million... (Who knows what he actually made through unlawful shorting)... And how much of a market cap did OWCP lose? I know Jeff owes me a lot of money.
I agree wholeheartedly. It may take a few years but patience will pay a 1000x over.
This is actually really great news because Australian regulations are very similar to FDA regs. With a larger population than Israel it may be possible to do some of the studies there and accelerate the timeline
According to the development timeline we should have the medical cream study results soon, announcing tablet info, and should have the cosmetic cream announcing plans to be sold. Know there were some meetings about orphan drug study too but that is likely still being reviewed.
No joke. Really pissed me off because I'm in both NTVA and OWCP. Both companies leadership are strong enough to stand in their own right. That said. If you have any info about the status of those SEC conversations any updates would be greatly appreciated.
I'm getting a little upset about this share registry. Anyone have any connections to demand some answers. Was this another Friedland fraud scheme? Just feel like we deserve some answers at this point. Especially with a founder who recently committed fraud and has been charged. Know the company isn't associated but we deserve to know what is happening to the shares he forfeited and the status of our shares with a clear plan moving forward.
How long would you expect for this matter to be settled? I still think 2019 and 2020 are going to be the years of many dollars. Looking forward to million dollar days. Still hanging on to all my shares and gathering more.
Thanks all for the cheap shares over the last few weeks. Still here and still holding strong as are many longs who just got tired of listening to the crap.
Let me ask this question. If someone told you for 15000 dollars today there was a high probability (greater than 50%) that in 2-3 years that money would be worth at least 1 million dollars. But there was also a small probability that it could be worth nothing. And in all likelihood you would at least be able to double your money in 12 months... would you do it?
People gamble with more than that on far worse odds every minute of every day. Nothing is certain but I like my odds, and still holding 300k shares and adding. I can wait till 2020 or even 2022 if needed to turn that into millions. Not worried about the day to day BS. I do agree that I would like to see timelines executed and more updates.
I wouldn't put money you needed here but if you were buying lotto tickets this is a far better way to make you wealthy.
Good luck to all... be patient... it's coming but it's taking a lot longer than any of us thought it would.
I'm going to post this for informational purposes only. To me it is complete garbage as there hasn't been a new shareholder letter and the English in this document is horrible. Take it for what you will.
https://www.mmjobserver.com/owc-pharmaceutical-research-corp-otcmktsowcp-issues-chairmans-statement-to-shareholders/29345/
On another note... did anyone else see a ask of 0.48... I got a feeling the safety trails data will be made available soon. I also think that our new Chairman showed that he was committed to hitting milestones when he released on time the last 10Q. I have been here for over a year and that had never happened until our new Chairman. Yes OWCP has been a habitual delay and disappointment but I'm hear for a reason and I think the team we have now will right our ship and get up sailing again.
Also... I wondering if Friedland will be forced to return the 7.5 million to OWCP in cash or if he will be forced to buy back 7.5 million worth of shares to return to OWCP.... or if OWCP does receive the Cash if they will buy the shares back and take them out of circulation.
This time when we run up we won't be coming back down because this time it will be on fundamentals.
That's the best thing that could have happened. Replace with a rock star CEO and less shares and even better...
This is all stupid. If the SEC felt OWCP did anything wrong we would know by now. Period... Nothing has been charged... and nothing will be charged. OWCP did not do anything wrong or the SEC would have dealt with it already.
Very true and very sad for many reasons.
The good news is that NTVA has a promising future and has (other than him formally bringing CEO) no association to this matter. SAD for the OWCP folks though but he was dumping through September which is when it reached hit's 52 week low then bounced up. With what was done there are others who will likely be charged... not the company but the brokers and transfer agencies. That stock has been manipulated for a long time. At least the SEC has eyes on it and will likely see it's PPS move up. Better yet... when news it won't drop in price.
It's written in plain english... Friedland provided the attorney letter... not OWCP
Get your facts right. Friedland provided the attorney opinion letter to the transfer agent.
That is not accurate. It states Friedland transfer agent.
Yeah I agree with you... That said I don't think it will be company leadership... it will be the market makers and brokers. Look at how the industry just dumped... look at CBNX from nearly 8 dollars to under a dollar. This is much larger but I don't think it has to do with the companies... it has to do with the market makers.
There is no grounds for a class action against OWCP at this time. There is however against JF and the disbarred lawyer and the broker who sold the shares illegally for him and his family.
Look when we started to move back up (end of September when Friedland stopped selling finally)... Perfectly explains why OWCP dropped every single time they had news. What do you think will happen when OWCP gets this 7 plus million for funding and sues his ass for this stuff. I'm buying more down here.